Readout LOUD: High Stakes for Huntington’s Patients

The Food and Drug Administration is scheduled to meet with ‍UniQure to discuss the future of its gene therapy for Huntington’s disease, a conversation that could significantly impact patients, according ⁢to patient advocate Lauren Holder.

UniQure ⁣and the FDA: huntington’s Disease Gene Therapy

The FDA’s evolving stance ‍on UniQure’s Huntington’s disease trial has prompted patient concerns and advocacy efforts, as discussed on the latest episode of ⁣STAT’s “The Readout LOUD”⁣ podcast. Holder details patient attempts to petition the agency to reconsider its position.More data about UniQure’s gene therapy is available here.

Huntington’s disease and Gene Therapy

Huntington’s disease is a progressive genetic disorder that causes the breakdown of nerve cells in the brain.The National Institute of Neurological Disorders and Stroke (NINDS) provides detailed information on the disease. Gene therapy ⁤aims to address the root cause of the disease by introducing a ⁤functional gene to replace the ‍defective one.

Medicare Drug Price Negotiations

The Centers for Medicare & Medicaid Services (CMS) recently announced a new ‍set of drug prices negotiated under the Inflation reduction Act. Fifteen drugs will be subject to price negotiations in the third round, potentially lowering costs for Medicare beneficiaries. The CMS announced the first 10 drugs selected for negotiation in August 2023.

Regenxbio Trial halt

The FDA has halted a gene‍ therapy trial conducted by Regenxbio. details of the trial shutdown are available on STAT News. ⁢The reason for the halt was not instantly disclosed in the STAT article.

Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.